JP2023078467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023078467A5 JP2023078467A5 JP2023057334A JP2023057334A JP2023078467A5 JP 2023078467 A5 JP2023078467 A5 JP 2023078467A5 JP 2023057334 A JP2023057334 A JP 2023057334A JP 2023057334 A JP2023057334 A JP 2023057334A JP 2023078467 A5 JP2023078467 A5 JP 2023078467A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- polypeptide
- seq
- polypeptides
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024195763A JP2025020347A (ja) | 2017-01-26 | 2024-11-08 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450804P | 2017-01-26 | 2017-01-26 | |
| US62/450,804 | 2017-01-26 | ||
| US201762487135P | 2017-04-19 | 2017-04-19 | |
| US62/487,135 | 2017-04-19 | ||
| JP2019541341A JP7305543B2 (ja) | 2017-01-26 | 2018-01-26 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| PCT/US2018/015595 WO2018140821A1 (en) | 2017-01-26 | 2018-01-26 | Tissue-specific wnt signal enhancing molecules and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541341A Division JP7305543B2 (ja) | 2017-01-26 | 2018-01-26 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195763A Division JP2025020347A (ja) | 2017-01-26 | 2024-11-08 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023078467A JP2023078467A (ja) | 2023-06-06 |
| JP2023078467A5 true JP2023078467A5 (enExample) | 2023-08-25 |
| JP7635291B2 JP7635291B2 (ja) | 2025-02-25 |
Family
ID=62978866
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541341A Active JP7305543B2 (ja) | 2017-01-26 | 2018-01-26 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| JP2023057334A Active JP7635291B2 (ja) | 2017-01-26 | 2023-03-31 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| JP2024195763A Withdrawn JP2025020347A (ja) | 2017-01-26 | 2024-11-08 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541341A Active JP7305543B2 (ja) | 2017-01-26 | 2018-01-26 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195763A Withdrawn JP2025020347A (ja) | 2017-01-26 | 2024-11-08 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11958891B2 (enExample) |
| EP (1) | EP3574019A4 (enExample) |
| JP (3) | JP7305543B2 (enExample) |
| CN (1) | CN110234662A (enExample) |
| AU (1) | AU2018211985B2 (enExample) |
| CA (1) | CA3050133A1 (enExample) |
| WO (1) | WO2018140821A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11993645B2 (en) | 2017-01-11 | 2024-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising R-Spondin (RSPO) surrogate molecules |
| JP7305543B2 (ja) | 2017-01-26 | 2023-07-10 | スロゼン オペレーティング， インコーポレイテッド | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| EP3728323A4 (en) | 2017-12-19 | 2022-01-26 | Surrozen Operating, Inc. | ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE |
| WO2019126398A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Wnt surrogate molecules and uses thereof |
| AU2018393076B2 (en) | 2017-12-19 | 2025-11-20 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
| WO2020014271A1 (en) * | 2018-07-09 | 2020-01-16 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses |
| CA3125274A1 (en) * | 2018-12-27 | 2020-07-02 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Bispecific antibody for membrane clearance of target receptors |
| US20220112278A1 (en) * | 2019-02-11 | 2022-04-14 | Surrozen, Inc. | Modulation of wnt signalling in ocular disorders |
| WO2020206005A1 (en) * | 2019-04-02 | 2020-10-08 | Surrozen, Inc. | Modulation of wnt signaling in auditory disorders |
| US20220315659A1 (en) * | 2019-06-11 | 2022-10-06 | AntlerA Therapeutics Inc, | Multivalent FZD and WNT Binding Molecules and Uses Thereof |
| WO2020257758A1 (en) | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors |
| KR102192471B1 (ko) * | 2019-10-18 | 2020-12-17 | 주식회사 인코스팜 | 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물 |
| US20240000890A1 (en) * | 2020-01-09 | 2024-01-04 | Retinal Solutions, LLC | Neural regeneration with synthetic protein administration |
| AU2021227662A1 (en) * | 2020-02-24 | 2022-09-01 | Surrozen Operating, Inc. | WNT super agonists |
| MX2023005032A (es) * | 2020-11-10 | 2023-05-16 | Scripps Research Inst | Anticuerpos para tratamientos con opioides. |
| JP2023549854A (ja) * | 2020-11-16 | 2023-11-29 | スロゼン オペレーティング， インコーポレイテッド | 肝臓特異的Ｗｎｔシグナル増強分子およびその使用 |
| CN112386687B (zh) * | 2020-12-09 | 2021-05-04 | 爱龄医美国际健康咨询服务(北京)有限公司 | 一种干细胞外泌体及其在药品和化妆品中的应用 |
| CN113307882B (zh) * | 2021-05-12 | 2022-12-20 | 东北大学 | 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物 |
| CN113293214A (zh) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | 一种检测神经母细胞瘤复发转移基因wnt2扩增的引物探针及其应用 |
| IL310154A (en) * | 2021-07-15 | 2024-03-01 | Diogenx | Recombinant variants of r-spondin proteins and their use |
| WO2023080159A1 (ja) * | 2021-11-02 | 2023-05-11 | レナセラピューティクス株式会社 | リガンド結合核酸複合体 |
| CN116789843B (zh) * | 2022-03-16 | 2024-09-17 | 伯桢生物科技(杭州)有限公司 | Wnt重组蛋白及其应用 |
| CN116836274B (zh) * | 2022-03-23 | 2024-11-22 | 东莞市朋志生物科技有限公司 | 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒 |
| JP2025525362A (ja) * | 2022-06-21 | 2025-08-05 | スロゼン オペレーティング， インコーポレイテッド | 角膜障害におけるｗｎｔシグナル伝達の調節 |
| WO2025146152A1 (zh) * | 2024-01-04 | 2025-07-10 | 上海宝济药业股份有限公司 | 一种药物组合物及其应用 |
| CN120647751B (zh) * | 2025-08-18 | 2025-12-02 | 成都迈科康生物科技有限公司 | 抗人乳头瘤病毒e1蛋白的抗体或其试剂盒和相关应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044409A1 (en) | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
| EP1673475B1 (en) * | 2003-10-10 | 2010-04-28 | Deutsches Krebsforschungszentrum | Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt |
| DE102004050620A1 (de) | 2004-10-13 | 2006-04-20 | Eberhard-Karls-Universität Tübingen | Monoklonaler Antikörper gegen Frizzled-Rezeptoren |
| DE102005035568A1 (de) | 2005-07-25 | 2007-02-01 | M-Phasys Gmbh | Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns |
| RS63964B1 (sr) | 2005-08-23 | 2023-03-31 | Univ Pennsylvania | Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu |
| CN101573383B (zh) | 2006-06-21 | 2015-05-13 | 肿瘤疗法科学股份有限公司 | 靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途 |
| EP2548576B1 (en) | 2006-08-14 | 2016-11-30 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis of cancer using anti-desmoglein-3 antibodies |
| JPWO2008093646A1 (ja) | 2007-02-01 | 2010-05-20 | 国立大学法人 奈良先端科学技術大学院大学 | Ｗｎｔシグナル伝達系活性化ペプチド |
| ES2663536T3 (es) | 2008-09-26 | 2018-04-13 | Oncomed Pharmaceuticals, Inc. | Agentes que se unen a receptores frizzled y usos de los mismos |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| PL3441458T3 (pl) | 2009-02-03 | 2023-11-06 | Koninklijke Nederlandse Akademie Van Wetenschappen | Podłoże do hodowli nabłonkowych komórek macierzystych i organoidów zawierających wspomniane komórki macierzyste |
| WO2010092457A1 (en) | 2009-02-10 | 2010-08-19 | Nokia Corporation | Method, apparatus and computer program product for transfer of capability support information in a multi-rat environment |
| EP2305274A1 (en) * | 2009-09-21 | 2011-04-06 | Centre National de la Recherche Scientifique (CNRS) | Use of WNT stimulators for treating demyelinating diseases |
| TWI488642B (zh) | 2009-12-09 | 2015-06-21 | Bayer Schering Pharma Ag | 抗－Ｃ４．４ａ抗體及其用途 |
| CN102971337B (zh) | 2010-04-01 | 2016-09-21 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
| EP2558571A4 (en) | 2010-04-16 | 2014-09-24 | Immune Disease Inst Inc | DELAYED POLYPEPTIDE EXPRESSION FROM MODIFIED SYNTHETIC RNAS AND USES THEREOF |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| BR112013024574B1 (pt) | 2011-03-29 | 2022-08-09 | Roche Glycart Ag | Anticorpo e uso do anticorpo |
| US10086043B2 (en) | 2011-04-03 | 2018-10-02 | The General Hospital Corporation | Efficient protein expression in vivo using modified RNA (MOD-RNA) |
| GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| CN109111523B (zh) | 2011-10-14 | 2022-06-07 | 诺华股份有限公司 | 用于Wnt途径相关疾病的抗体和方法 |
| WO2013071047A1 (en) | 2011-11-11 | 2013-05-16 | Children's Medical Center Corporation | Compositions and methods for in vitro transcription of rna |
| WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| ES2797533T3 (es) | 2012-02-28 | 2020-12-02 | Novartis Ag | Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43 |
| HK1206612A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
| CA2878626A1 (en) | 2012-08-09 | 2014-02-13 | Roche Glycart Ag | Asgpr antibodies and uses thereof |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
| WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| SG11201608715WA (en) | 2014-04-21 | 2016-11-29 | Abbvie Stemcentrx Llc | Novel antii-rnf43 antibodies and methods of use |
| US11142577B2 (en) | 2014-09-12 | 2021-10-12 | The Board Of Trustees Of The Leland Stanford Junior University | WNT signaling agonist molecules |
| CA2965960A1 (en) | 2014-10-27 | 2016-05-06 | Agency For Science, Technology And Research | Anti-tim-3 antibodies |
| WO2016073906A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related immunoassays |
| JP6993228B2 (ja) | 2014-11-19 | 2022-03-03 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法 |
| MA45420A (fr) | 2015-04-17 | 2019-05-01 | Merrimack Pharmaceuticals Inc | Traitements combinés avec seribantumab |
| KR20250157457A (ko) * | 2015-10-23 | 2025-11-04 | 메뤼스 엔.페. | 암 성장을 억제하는 결합 분자 |
| IL287019B2 (en) | 2015-12-08 | 2025-10-01 | Regeneron Pharma | Preparations and methods for internalizing enzymes |
| US20170349659A1 (en) | 2016-06-03 | 2017-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Wnt signaling agonist molecules |
| WO2018107116A1 (en) | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| US11993645B2 (en) | 2017-01-11 | 2024-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising R-Spondin (RSPO) surrogate molecules |
| JP7305543B2 (ja) | 2017-01-26 | 2023-07-10 | スロゼン オペレーティング， インコーポレイテッド | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| JP2020518584A (ja) | 2017-05-02 | 2020-06-25 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
| GB201708330D0 (en) | 2017-05-24 | 2017-07-05 | Koninklijke Nederlandse Akademie Van Wetenschappen | Fusion protein for enhancing intestinal regeneration |
| AU2018393076B2 (en) | 2017-12-19 | 2025-11-20 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
| EP3728323A4 (en) | 2017-12-19 | 2022-01-26 | Surrozen Operating, Inc. | ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE |
| WO2019126398A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Wnt surrogate molecules and uses thereof |
| US20210292422A1 (en) | 2018-07-05 | 2021-09-23 | Surrozen, Inc. | Multi-specific wnt surrogate molecules and uses thereof |
| WO2020014271A1 (en) | 2018-07-09 | 2020-01-16 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses |
| US20220064337A1 (en) | 2018-12-19 | 2022-03-03 | Surrozen, Inc. | Antigen binding formats for receptor complexes |
| US20220112278A1 (en) | 2019-02-11 | 2022-04-14 | Surrozen, Inc. | Modulation of wnt signalling in ocular disorders |
| KR20210138023A (ko) | 2019-03-11 | 2021-11-18 | 서로젠, 인크. | 위장 장애에서 wnt 신호 전달의 조절 |
| WO2020206005A1 (en) | 2019-04-02 | 2020-10-08 | Surrozen, Inc. | Modulation of wnt signaling in auditory disorders |
| US20220315659A1 (en) | 2019-06-11 | 2022-10-06 | AntlerA Therapeutics Inc, | Multivalent FZD and WNT Binding Molecules and Uses Thereof |
| US11050604B2 (en) | 2019-07-01 | 2021-06-29 | Rampart Communications, Inc. | Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation |
| AU2021227662A1 (en) | 2020-02-24 | 2022-09-01 | Surrozen Operating, Inc. | WNT super agonists |
| JP2023549854A (ja) | 2020-11-16 | 2023-11-29 | スロゼン オペレーティング， インコーポレイテッド | 肝臓特異的Ｗｎｔシグナル増強分子およびその使用 |
| EP4305070A4 (en) | 2021-03-10 | 2025-04-30 | Surrozen Operating, Inc. | MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERS |
-
2018
- 2018-01-26 JP JP2019541341A patent/JP7305543B2/ja active Active
- 2018-01-26 CA CA3050133A patent/CA3050133A1/en active Pending
- 2018-01-26 CN CN201880008831.XA patent/CN110234662A/zh active Pending
- 2018-01-26 AU AU2018211985A patent/AU2018211985B2/en active Active
- 2018-01-26 US US16/481,001 patent/US11958891B2/en active Active
- 2018-01-26 WO PCT/US2018/015595 patent/WO2018140821A1/en not_active Ceased
- 2018-01-26 EP EP18744610.9A patent/EP3574019A4/en active Pending
-
2023
- 2023-03-31 JP JP2023057334A patent/JP7635291B2/ja active Active
-
2024
- 2024-03-06 US US18/597,679 patent/US20240279303A1/en active Pending
- 2024-11-08 JP JP2024195763A patent/JP2025020347A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023078467A5 (enExample) | ||
| JP2020506701A5 (enExample) | ||
| JPWO2020014271A5 (enExample) | ||
| JP2007513634A5 (enExample) | ||
| AU2016289492B2 (en) | Vaccine against RSV | |
| RU2010122053A (ru) | Иммуносупрессорные полипептиды и нуклеиновые кислоты | |
| JP2020023517A5 (enExample) | ||
| JP2016052315A5 (enExample) | ||
| NO995689L (no) | Forbindelser for immunoterapi og diagnose av tuberkulose og metoder for deres anvendelse | |
| JP2014510518A5 (enExample) | ||
| JP2005120106A5 (enExample) | ||
| RU2012113162A (ru) | Белок слияния, содержащий тимусный стромальный лимфопоэтический белок, вакцина, содержащая эскпрессионный вектор для экспресии белка, и вакцина, содержащая указанный вектор для экспрессии | |
| JP2017512063A5 (enExample) | ||
| JP2018537087A5 (enExample) | ||
| JP2023029902A5 (enExample) | ||
| JP2005245460A5 (enExample) | ||
| JP2009525757A5 (enExample) | ||
| CN115443288A (zh) | 一种免疫球蛋白降解酶IdeE的突变体 | |
| FI4034555T3 (fi) | Dap10/dap12-fuusiopolypeptidit | |
| EA200901441A1 (ru) | Новые молекулы антител и нуклеиновых кислот, связывающиеся с грибным белком теплового шока hsp90 | |
| JP2020517260A5 (enExample) | ||
| RU2008138536A (ru) | Химерные вакцинные антигены против вируса классической чумы свиней | |
| JP2023086734A5 (enExample) | ||
| RU2010152357A (ru) | Адапторная молекула для доставки аденовирусных векторов | |
| WO2024047090A3 (en) | Modified virus-like particles of cmv |